CRI study high­lights CT­LA-4's mar­quee role in PD-1/L1 com­bos — de­spite an in­creas­ing­ly trou­bled clin­i­cal pro­file

Yes­ter­day, we of­fered up a look at the broad range of im­muno-on­col­o­gy stud­ies now un­der­way the world over, as gath­ered by re­searchers at the Can­cer Re­search In­sti­tute for their sec­ond an­nu­al ex­am­i­na­tion of the land­scape. But be­fore we turn the page, I thought it would be in­struc­tive to fo­cus on one crit­i­cal as­pect of the re­port that has ma­jor im­pli­ca­tions for this boom­ing R&D sec­tor.

The CRI’s as­sess­ment not on­ly breaks out the 2,250 PD-1/L1 stud­ies now in the clin­ic — up by 748 tri­als from a year ago — they al­so break out which com­bos are most pop­u­lar.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER